Efficacy and safety of application of autologous platelet rich plasma (PRP) combined with intrauterine situable balloon in repairing damaged endometrium

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025846

Enrollment

Unknown

Registered

2019-09-11

Start date

2019-09-10

Completion date

Unknown

Last updated

2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine adhesions

Interventions

Experimental group:PRP

Control group:No PRP

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Previously diagnostic hysteroscopy confirmed moderate or severe adhesions, AFS score >= 5; 2. Desiring to conceive; 3. Ages between 20-40 years; 4. Normal endocrine level and regular ovulation; 5. Signing informed consent.

Exclusion criteria

Exclusion criteria: 1. Hysteroscopy contraindications; 2. Hormone therapy contraindications; 3. Pregnancy contraindications; 4. Other uterine complications (eg. endometritis, congenital uterine malformations, severe adenomyosis, submucosal myoma,etc.); 5. History of malignant pelvic tumor and radiotherapy; 6. Severe hepatic or renal dysfunction; 7. Complicated with hematological disorders (eg.platelet dysfunction, severe anemia, blood-borne infections); 8. Other infertile factors (eg. endocrine abnormality, PCOS, premature ovarian failure or early onset ovarian insufficiency); 9. Male factor infertility(eg.seminal abnormalities).

Design outcomes

Primary

Measure	Time frame
Recurrence rate of IUA;AFS score;	—

Secondary

Measure	Time frame
Menstrual blood volume;Rate of pregnancy;	—

Countries

China

Contacts

Public ContactHua Duan

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

duanhua888@163.com+86 13501019066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026